Advancing Precision Oncology through Long-Read RNA Sequencing

Wobble Genomics integrates ATLUS Targeting, Level-Up™, and TAMA™ to deliver a complete RNA platform — from enhanced detection to precise targeting and AI-driven insight.

Enabling deeper biology, better decisions, and improved outcomes across research and drug development.

Overview

Long-read RNA sequencing captures full-length transcripts in a single read, providing a more complete and accurate view of cancer biology.

This reveals critical RNA variation missed by conventional methods, improving biomarker discovery, patient stratification, and target identification.

The Technology

Unlike traditional short-read approaches, long-read sequencing analyses RNA end to end. This enables precise detection of isoforms, gene fusions, and structural variations that are often central to disease.

Applications

In diagnostics, this improves the identification of clinically relevant biomarkers and supports more confident treatment decisions.

In drug development, it enables better target discovery, mechanism validation, and monitoring of treatment response, thereby supporting the development of more effective therapies.

Why it matters

By providing a more complete and actionable view of RNA, long-read sequencing helps reduce risk, improve clinical success, and accelerate precision medicine.